A PCR assay was developed to detect known and as yet unidentified papillomaviruses (PVs). For this purpose we analysed the conserved amino acid sequences in the L1 and E1 open reading frames of 45 human and nine animal PVs. Candidate regions for the design of a primer were identified as those having the least number of amino acid and nucleotide sequence variants among the different PVs. These regions in the L10RF have been described previously. We modified the sequences of the backward and the forward primers, as well as the sequence of the oligonucleotide used as the degenerate probe, in order to cover a broader spectrum of PVs. The sensitivity of the assay for the human and animal PVs tested after hybridization with a 32P-labelled degenerate oligonucleotide probe was one genome copy per cell for integrated PV DNA and 10 genome copies per cell for plasmid PV DNA. The only exceptions were human papillomavirus (HPV) type 4, HPV60 and HPV65, for which a lower sensitivity was obtained. This group could be detected only by using additional primers. The assay was used to analyse 85 lung cancer biopsies representing different histological types. Using this system no PV DNA sequences were detected in the biopsies when compared with human placental DNA (a negative control) and PV DNA-positive standards.
Introduction
Presently the genus papillomavirus (PV) comprises a group of 70 human papillomaviruses (HPVs) and an increasing number of animal types. The HPVs have been associated with benign and malignant lesions of the mucosa, mainly of the genital tract, and of the skin (zur Hausen, 1989) . The possible involvement of HPV in the aetiology of malignant tumours of the respiratory tract has been implicated by zur Hausen (1976) . Syrj/inen (1980) suggested a role for HPVs in the development of squamous cell carcinomas of the lung, based on histological data. Subsequently, HPV DNA was detected in several isolated cases of lung squamous cell carcinomas (Stremlau et aL, 1985; Byrne et al., 1987; Helmuth & Strate, 1987; Ostrow et al., 1987; Syrj~inen & Syrj/inen, 1987; Guillon et al., 1991; DiLorenzo et al., 1992; Popper et al., 1992; Yousem et al., 1992) , although large numbers of biopsies have been screened (Stremlau et al., 1985; Ostrow et al., 1987; E.-M. de Villiers, unpublished results) .
The detection of unidentified PVs has been hampered by the probes used for low-stringency hybridization, which are limited to DNA of known types. Low copy numbers of distantly related HPVs would not normally be detected with this method. However, in exceptional cases this has been achieved by ethidium bromide staining, notably in certain skin warts (Grimmel et aI., 1988) . Cloning could then allow subsequent characterization of new HPV types.
More recently, PCR has been utilized in the detection of PVs. These assays allow the amplification of selected parts of viral genome, such as E6-E7 (Fujinaga et al., 1991) , E1 (Gregoire et al., 1989; van den Brule et al., 1990) or L1 (Manos et al., 1989; van den Brule et al., 1990; Snijders et al., 1990 Snijders et al., , 1991 Yoshikawa et al., 1991) for the detection of a broad spectrum of PVs.
The purpose of this study was to develop a general PCR assay which would enable us to detect not only the known PV types, but also very distantly related and as yet unidentified types. For this reason, the conserved amino acid sequences in the L1 and E1 open reading frames (ORFs) of 45 human and nine animal PVs were analysed. The candidate regions for the design of a primer were identified as having the least number of amino acid and nucleotide sequence variations among different PVs. The most conserved sequences were located in the L10RF. These regions happened to coincide with the primer regions previously described by Snijders et al. (1991) . We extended the sequence range of the primers not only to cover a broader range of known PVs but also to attempt to detect unknown, distantly related PV types. HPV2, 3 §, 7, 16, 17, 18, 25, 27, 30, 31, 32, 34, 35, 42, 45, 49, 53, 56 HPV19, 51; BPV1; DPV HPVI, 5, 6, 8, 9, 11, 12, 13, 14, 15, 26, 33, 39, 41, 47, 52, 58, 63 General * The sequence begins with a BamHI linker (not shown) at the 5' end of both types of primer, but not the probe. M denotes either A or C; R denotes A or G; S denotes C or G; W denotes A or T; Y denotes C or T. X means any of the four nucleotides may appear.
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t The sensitivity of detection of PV types shown in bold was tested (either from cloned genomes or as present in cell lines). $ Two bases mismatch in the primer region. § One base mismatch. I1 Covers all HPVs except HPV1, 4, 60 and 65.
Methods
Clinical samples. A total of 85 lung tumour biopsies were examined. These represented the following histological types (number of cases in parentheses): squamous cell carcinoma (34), adenocarcinoma (13), bronchial carcinoma (24), large cell bronchial carcinoma (eight), small cell bronchial carcinoma (four), melanosarcoma (one) and carcinoid tumour (one). Samples were stored at -70 °C.
DNA extraction. All possible measures were taken to avoid crosscontamination of samples during the DNA extraction procedures. Frozen tumour samples were processed in a laminar flow hood. Tissue was digested with proteinase K (100 gg/ml) in the presence of 0.5 % SDS for 2 h at 56 °C. This was followed by phenol~zhloroform-isoamyl alcohol extraction and precipitation with ethanol. The integrity and concentration of the DNA were determined by agarose gel electrophoresis.
Computer-assisted analysis of PV proteins and nucleic acids. The HUSAR software package (Deutsches Krebsforschungszentrum and Center of Molecular Biology, University of Heidelberg) was used for comparative analyses of the nucleic acid and protein sequences. For the final design of PCR primers and the probe, the L10RF sequences of the following 45 human and nine animal PVs were used: HPV 1 to 4, 5b, 5c, 6 to 19, 25 to 27, 30 to 34, 35, 35H, 39 to 42, 45, 47, 49, 51 to 53, 56 to 58, 63 and 65, bovine PV (BPV) 1, 2 and 4, canine oral PV (COPV), deer PV (DPV), European elk PV (EEPV), pygmy chimpanzee PV (PCPV), rhesus PV (RhPV) 1 and cottontail rabbit PV (CRPV). The published PV DNA sequences were obtained from the EMBL Data Bank and the data for unpublished HPV sequences were as described by Delius & Hofmann (1994) .
Oligonucleotides. The oligonucleotides used as primers and as the probe are listed in Table 1 . Synthesized oligonucleotides were dissolved in water to 10 pmol/~d and stored at -20 °C. In order to obtain more degenerate primer mixtures, the oligonucleotides were mixed proportionately to their degeneracy numbers. The following abbreviations were used for mixtures of the primers: B, mixture of oligonucleotides F2, F3 and F4 in the ratio 2:2:1 ; B1, mixture of oligonncleotides F10, F11 and F12 in the ratio 2: 2: 1 ; C, mixture of oligonucleotides B5, B6 and B7 in the ratio 2: 2: 1. The degeneracy numbers for these mixtures are 2560, 2560 and 1280 respectively. and buffer (Promega). After preheating to 65 °C in a thermal cycler (Perkin-Elmer Cetus), the reaction was started by a denaturation step (5 min at 94 °C). This was followed by 39 cycles of amplification, each including denaturation (1 min at 94 °C), annealing (2 rain at 52 °C) and extension at 72 °C. The initial extension time of 1 rain was prolonged by 2 s for each additional cycle to compensate for the partial thermal inactivation of the Taq polymerase (Innes & Gelfand, 1990) . After completion of the cycles, a final step of 6 min at 72 °C was performed, followed by cooling to 4 °C. The enzyme was inactivated with 5 gl 0.1 M-EDTA pH 8.0 and 50 gl of chloroform. After the chloroform extraction, 10 gl of each sample was analysed by gel electrophoresis in 1.5 % agarose.
Southern blot analysis. After electrophoresis the gel was treated with denaturation buffer (1.5 M-NaC1, 0.5 M-NaOH), transferred onto a nylon membrane (GeneScreen; Dupont) and, after neutralization (20x SSC, 0.5 M-Tri~HCI, pH 8.0), it was cross-linked using u.v. irradiation (Stratalinker; Stratagene).
Probe.
A degenerate oligonucleotide (80 pmol) was labelled with 250 laCi [y-a2P]ATP (> 5000 Ci/mmol; Amersham) using 10 units of T4 polynucleotide kinase (New England Biolabs) in a final volume of 50 gl.
Hybridization. This was performed for 24 h at 37 °C in a solution consisting of 6 x SSC, 0.5% SDS, 2.5 x Denhardt's solution and 200 gg/ml of tRNA. The labelled probe was added at a concentration of 16 pmol/ml (1 ml per 37 cm e of membrane). After hybridization, the filters were washed four times (20 min at 37 °C in 6 x SSC and 01% SDS) and exposed to a Kodak X-Omat film using an intensifiying screen for 24 h.
Results

PCR primers and probe design
The analysis of the sequence and amino acid alignments in the E1 and L10RFs of 45 HPVs and nine animal PVs revealed a number of conserved regions. The regions having the lowest amino acid sequence variation and subsequently deduced lowest nucleotide sequence variation between the different PVs were localized in the L1 ORF. For example in HPV18 these were at nucleotide positions 5934 to 5953 (used for the forward primer), 6561 to 6580 (backward primer) and 6195 to 6212 (probe). This results in a PCR product of approximately 650 bp. We selected these regions for designing the degenerate forward and backward primers, as well as a degenerate oligonucleotide to be used as probe. The sequences of these primers included all possible codons for the conserved amino acid regions. To minimize the number of primers, amino acid substitutions which would have a single nucleotide change in the primer were not included (exceptions were the HPV3, CRPV, HPV4 and HPV65 primers). The regions used resulted in some primers which have been previously described (forward primers GP17 and MY09; Snijders et al., 1991 and Manos et al., 1989; backward primer GP18; Snijders et al., 1991) . Also, the degenerate oligonucleotide for the probe partially overlaps the GPR22 probe (Snijders et al., 1991) .
Nucleotide sequence variations were deduced from an amino acid pattern common for the majority of PVs analysed, as well as the amino acid substitutions specific for certain PVs (Fig. 1 ). In the forward primer region (Fig. 1 a) a common motif GRGQPLG is present in the majority of HPV types and in three animal PVs (COPV, PCPV1, RhPV1). The glycine at position 1 in the sequence appears to be only moderately conserved. Three HPV types (HPV8, HPV12 and HPV41) and the animal PVs BPV1, BPV2, DPV and EEPV have the amino acid serine at this position. Further substitutions are cysteine in BPV4 and asparagine in CRPV. A further variation is present at position 4 where the glutamine has been replaced by leucine (in HPV3) or glycine (in HPV4 and HPV65). A common motif for the majority of HPVs in the backward primer region is QGHNNGI (Fig. 1 b) . Two variable positions (histidine at position 3 and isoleucine at position 7) are present in this sequence. The histidine is substituted for a methionine in five (BPV1, BPV2, CRPV, DPV and EEPV) of the nine animal PVs examined, whereas other amino acids are found at this position in HPV1, HPV4, HPV65, BPV4 and COPV. The isoleucine at position 7 is not strictly conserved, as it may be substituted by a methionine (in HPV2 and HPV57) or a valine (in HPV18).
A similar analysis of the probe region showed that the pattern I(E or Q)DGDM is common in many human and animal PVs. The only exceptions are at position 1, where leucine is found in HPV18 and HPV35, and at position 4 where an alanine appears in HPV41 (Fig. 1 c) .
Primers with a maximum degeneracy number of 512 can be used successfully in PCR, because a higher degeneracy may result in poor specificity (Compton, 1990) . In our analyses, the numbers of variants in the nucleotide sequence which can be deduced from the amino acid sequences after the variations have been included are 96768 for the forward primer, 4352 for the backward primer and 1152 for the probe oligonucleotide. A reduction in the degeneracy number of the primers could be obtained by subdividing these variants into groups of sequences represented by different oligonucleotides (Table l) . Each of these oligonucleotides was synthesized and used either on its own or in different mixtures. To minimize the number of primers, amino acid substitutions leading to a change of a single nucleotide in the primer were not included.
In the probe region a single oligonucleotide, P1, covers all the possible nucleotide sequence variations which were deduced from the amino acid sequence data.
Sensitivity, generality and specificity of the assay
The sensitivity and generality of the assay was evaluated using dilutions of PV recombinant plasmid DNA, mixed with human placental DNA as a control (Fig. 2) . The forward and backward primers that were used for each PV type are listed in Table 2 . For the majority of PVs tested, a sensitivity of 100 copies/cell was obtained after gel electrophoresis and ethidium bromide staining (Fig.  2a ), and 10 copies/cell after hybridization of the corresponding blot with the a2P-labelled degenerate oligonucleotide probe (Fig. 2 b) . DNA from the cervical carcinoma cell lines SiHa (one genome copy of HPV16/ cell), CaSki (600 genome copies of HPV16/cell) and HeLa (20 to 40 genome copies of HPV18/cell) were included as positive controls. In all cases, bands of the expected size were visible after ethidium bromide staining.
To investigate the specificity of the amplification, the following DNA samples were used: human placenta, bacterial, phage lambda and pBlueScript plasmid vector. 4) ; primers B and C (lanes 6 to 9); or primers F4 and B5 (lanes 11 to 14) . Lane C is a placental DNA amplification alone, as a control. The arrow indicates the expected position of a PV-specific PCR product and the arrowhead indicates the amplified cellular sequences.
Against the background of the cellular DNA, additional distinct bands were visible after ethidium bromide staining, varying in intensity depending on the primer combinations used (Fig. 2 a) . However, these bands did not show increased intensity when hybridized to the probe (Fig. 2b) . They could therefore be used as an internal control of the amplification efficiency because the different samples tested all have a uniform intensity (Fig. 3a) . The sequence variants included in the degenerate oligonucleotides had a range of melting temperatures (Tin). The lowest T m calculated for one of these variants was 52 °C. Therefore an annealing temperature of 47 °C (T m-5 °C) was tested in the PCR assay. This resulted in an increase in the background, and a decrease in sensitivity of more than 10-fold ( Fig. 4a and b) . This was probably caused by non-specific annealing of the mixture of primers. To avoid this, an annealing temperature of 52 °C was subsequently selected for amplifying the tumour DNA.
To evaluate the relationship between the degeneracy of the primers and the sensitivity of the PCR assay, HPV33 DNA was amplified using each oligonucleotide separately and compared with amplification using primer mixtures. An increase in the primer degeneracy from 262144 (512x512; primers F4 and B5) to 10616832 (4608 x 2304; primer mixtures A + B with C + B8) resulted in a 100-fold reduction in the sensitivity. To maintain a balance between the number of experiments which could be performed and the sensitivity which could be obtained, the forward primers A, A1, B and B1, and the backward primers C and BS, were chosen for the initial screening of the lung turnout samples. The results of the amplification of different control samples of PV DNA with various primer combinations are summarized in Table 2 .
Screening of lung tumour biopsies
The cellular DNA from the 85 lung tumour biopsies was amplified with each of the different primer combinations. None of the DNA samples contained detectable PV sequences (Fig. 3) .
Twenty-eight biopsies (including 24 squamous cell carcinomas) were screened with the primers covering the HPV4 nucleotide sequence (primers E and B8). These results were all negative.
Discussion
In the present study we have developed a generalized PV PCR assay covering a broader spectrum of PVs than described previously by Snijders et al. (1991) . A set of degenerate forward and backward primers and a single degenerate probe were designed. These corresponded to the nucleic acid sequence variations deduced from the conserved amino acid sequences in the L10RF of 45 human and nine animal PVs.
The conserved regions in the L1 and E10RFs of the PV genome were evaluated. The regions in L1 gave the least number of amino acid and nucleotide sequence variations and would therefore require the production of fewer primers having a relatively low degeneracy. An additional reason for selecting the L1 region for the primer design was that, according to the limited data available, this ORF seems to be less prone to disruption during integration of the PV genome into cellular DNA (Schwarz et al., 1985; Wagatsuma et al., 1990) .
A number of primers were designed (Table 1) which cover the majority of PVs. A combination of the oligonucleotides A, F2, F3 and F4 cover the major motif of the forward primer region, GRGQPLG, whereas oligonucleotides A1, F10, F11 and F12 cover variations resulting from the change of the glycine (position 1) to a serine. Combined, these eight oligonucleotides account for all nucleotide sequence variations in the forward primer region with the exception of those of HPV3, CRPV, HPV4 and HPV65. A mixture of oligonucleotides A-F~F3-F4 (in the ratio 4:2:2:1) would be comparable to the GP17 primer (Snijders et al., 1991) but less degenerate and therefore presumably more specific. In the backward primer region, the oligonucleotide B5 corresponds to the major HPV pattern, B6 to HPV1, B7 to certain animal PVs and B8 to HPV4, BPV4 and COPV. B7 differs from B8 in two nucleotides and is more specific to certain animal PV types. B8 could nevertheless be used to cover a broader spectrum of animal PVs. Oligonucleotide B5 is identical to the GP18 primer (Snijders et al., 1991) .
The substitution of the glycine for serine at position 1 in the region of the forward primer occurs in a number of human and animal PV types (Fig. 1) . Two sets of forward primers were designed which included codons for either glycine (primers A and B) or serine (primers A1 and B1), the only difference being two base changes (GG to TC) at the 5 / end of the oligonucleotide. These two sets of primers were used to compare the efficiency of the amplification of different PVs. The sensitivity of detection was comparable for the majority of PVs using either of the forward primers (B or B1). However, in some cases one primer gave a much higher amplification than the other. For example, with BPV1 DNA the sensitivity increased 100-fold when using the B 1 forward primer (Fig. 4b) . Similarly, HPV3 is amplified more efficiently with B primer. This underlines the necessity to include both sets of primers in order to achieve maximum amplification of the majority of sequences.
The efficiency of amplification of HPV4 (including the related HPV60 and HPV65) was very poor when using the general primers. The problem could be attributed to the amino acid at position 4 in the conserved sequence, where the glutamine is substituted for a glycine in HPV4 (two nucleotides mismatch). HPV3 contains a leucine at this same position (causing one nucleotide to mismatch), but this did not affect the efficiency of the amplification. Initially, a forward primer (primer E) was designed to cover the HPV4 pattern specifically. This improved the detection level, but the sensitivity obtained was still as low as 100 genome copies/cell after hybridization. Only after the subsequent use of an additional set of six primers (Table 1) could the sensitivity for this group of HPV types be increased to a level of 10 genome copies/cell (visible after ethidium bromide staining) for HPV4 and HPV60. These primers are obviously more specific than the group of primers described for all other PV types included in this study.
All the primers described amplify cellular DNA sequences as well. Although the sizes of these bands usually differed from the expected size of the PV amplified product, this could create problems in identi-fying PV-specific products. A number of these amplified products were cloned and on comparison their sequences were found to be homologous to repetitive sequences present in cellular DNA (data not shown). Certain sequences of the lambda phage DNA were not only amplified with these primers, but hybridized with the degenerate probe resulting in a positive signal. These data prove that the identification of the amplified products as PV sequences could only be confirmed after the cloning of such sequences or by direct cyclesequencing of the extracted products.
Theoretically, the sequence in the conserved region of the L 10RF allows for 4608 forward and 2304 backward primer variations. The combination of these would lead to 1.06 × 107 variations in the DNA sequence, and even more if a few mismatches within a primer were to be tolerated in PCR. Only 54 of these variations actually correspond to the DNA sequences of the PVs included in this study, leaving a large number of possible sequences which could cover any other known or unknown PV type. It is, of course, impossible to test whether all such sequences would be amplified with the same efficiency as was found for the types tested (one genome copy/cell of integrated and 10 genome copies/cell of cloned PV after hybridization with the degenerate probe).
An important consideration is the feasibility of such an assay. If one includes all the possible sequence variations deduced from a substitution in only one codon in the middle of each primer, this would lead to 16 forward and 16 backward primers, provided the rest of the oligonucleotide sequence remained constant. One sample would then have to be tested with 256 primer combinations. Apart from the limited amount of tumour DNA usually available, the screening of larger numbers of tumours would not be practical. In this study we attempted to combine practicality, sensitivity and specificity in the use of degenerate primers and a degenerate probe to screen a large number of malignant lung tumour samples. Within the limitations discussed previously, we could not detect any PV sequences in these samples.
